Alpha 2.0
Login Register
» Authors » Kyeongmi Cheon

Kyeongmi Cheon

Explore the profile of Kyeongmi Cheon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 146
Followers 0
Related Specialties
Public Health
Science
Allergy & Immunology
Top 10 Co-Authors
Alain Luxembourg
Paul S Albert
Michael J Hafey
Frank D Sistare
Gretchen Tamms
Luwy Musey
Zhiwei Zhang
Hong Duong
Thomas Group
Sonali Rawat
Published In
Toxicol Sci
Stat Med
Vaccine
Proc Natl Acad Sci U S A
Accid Anal Prev
Affiliations
Soon will be listed here.
Recent Articles
1.
Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
Nolan K, Seaton B, Antonello J, Zhang Y, Cook L, Delfino K, et al.
mSphere . 2023 Mar; 8(2):e0096221. PMID: 36926984
Two multiplex immunoassays are routinely used to assess antibody responses in clinical trials of the 9-valent human papillomavirus (9vHPV) vaccine. The HPV6/11/16/18/31/33/45/52/58 competitive Luminex immunoassay (HPV-9 cLIA) and HPV6/11/16/18/31/33/45/52/58 total...
2.
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, et al.
Vaccine . 2023 Jan; 41(5):1142-1152. PMID: 36621410
Background: Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine...
3.
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
Hammitt L, Quinn D, Janczewska E, Pasquel F, Tytus R, Reddy K, et al.
Open Forum Infect Dis . 2022 Feb; 9(3):ofab605. PMID: 35146039
Background: Adults with certain medical and behavioral factors are at increased risk for pneumococcal disease (PD). Sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine...
4.
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
Giuliano A, Wilkin T, Bautista O, Cheon K, Connor L, Dubey S, et al.
Contemp Clin Trials . 2021 Oct; 115:106592. PMID: 34678491
Background: Seven high-risk human papillomavirus (HPV) types (16/18/31/33/45/52/58) covered by the 9-valent HPV (9vHPV) vaccine cause >90% of HPV-related head and neck cancers (HNCs). An ongoing clinical trial (NCT04199689) was...
5.
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
Thiem V, Quang N, Tuan N, Cheon K, Gallagher N, Luxembourg A, et al.
Hum Vaccin Immunother . 2021 Apr; 17(7):1980-1985. PMID: 33844623
This open-label, single-center, Phase 3 study (NCT03546842) assessed the immunogenicity and safety of the nine-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine in Vietnamese males and females, with the aim to support...
6.
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
Joura E, Ulied A, Vandermeulen C, Rua Figueroa M, Seppa I, Hernandez Aguado J, et al.
Vaccine . 2021 Mar; 39(20):2800-2809. PMID: 33676783
Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16-26 years of age. We present a phase 3...
7.
Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity
Li Y, Evers R, Hafey M, Cheon K, Duong H, Lynch D, et al.
Toxicol Sci . 2019 Mar; 170(1):180-198. PMID: 30903168
Inhibition of the bile salt export pump (BSEP) may be associated with clinical drug-induced liver injury, but is poorly predicted by preclinical animal models. Here we present the development of...
8.
Antibiotic-Induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition
Li Y, Hafey M, Duong H, Evers R, Cheon K, Holder D, et al.
Toxicol Sci . 2017 Jan; 157(1):30-40. PMID: 28108666
Drug-induced liver injury (DILI) is a common toxicity observed in drug development and can lead to withdrawal of approved drugs from the market. To better understand the numerous mechanisms of...
9.
On exchangeable multinomial distributions
George E, Cheon K, Yuan Y, Szabo A
Biometrika . 2016 Jun; 103(2):397-408. PMID: 27279665
We derive an expression for the joint distribution of exchangeable multinomial random variables, which generalizes the multinomial distribution based on independent trials while retaining some of its important properties. Unlike...
10.
Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys
Tozzo E, Bhat G, Cheon K, Camacho R
PLoS One . 2015 May; 10(5):e0126642. PMID: 25954816
Hyperinsulinemic-euglycemic clamps are considered the "gold standard" for assessing whole body insulin sensitivity. When used in combination with tracer dilution techniques and physiological insulin concentrations, insulin sensitization can be dissected...